|
AU2020220204B1
|
|
Method and compositions for treating Coronavirus infection
|
|
US10729735B1
|
|
Method and compostitions for treating coronavirus infection
|
|
WO2020242752A1
|
|
Method and compositions for treating htlv-1 virus infection
|
|
US2019328809A1
|
|
Method and compositions for treating viral infection
|
|
US2019175634A1
|
|
Method and compositions for treating viral infections
|
|
KR20200083969A
|
|
Methods and neuroprotective compositions for treating neurological conditions
|
|
WO2019055119A1
|
|
Method and composition for treating viral infection
|
|
WO2018053123A1
|
|
Method and compositions for treating viral infection
|
|
US2018042976A1
|
|
Method of treating neurological conditions with extract of Nerium species or Thevetia species
|
|
US2018000852A1
|
|
Method of treating neurological conditions with oleandrin
|
|
US2015283191A1
|
|
Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species
|
|
CN103429251A
|
|
Method of treating neurological conditions with extract of nerium species or thevetia species
|
|
CN102834010A
|
|
Method of treating neurological conditions with cardiac glycosides
|
|
KR20100087730A
|
|
Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
|
|
US2006188536A1
|
|
Particles from processing of oleander leaves
|
|
US2007026092A1
|
|
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
